急性呼吸窘迫综合征精准治疗探索的新型转化研究路径
该综述回顾了急性呼吸窘迫综合征(ARDS)被首次描述50年来在危险因素、致病机制及血浆和支气管肺泡灌洗液蛋白表达模式方面的研究进展,指出尽管有这些努力,ARDS的药物治疗选择仍然匮乏。作者分析了患者异质性、药物反应差异及靶点选择可能不当等原因,并讨论了可推动ARDS精准医学方法的生物学与分析技术。
要点
- ARDS药物治疗选择仍匮乏,患者异质性与药物反应差异是常被提及的原因。
- 血浆和支气管肺泡灌洗液蛋白表达模式已被用于表征ARDS患者。
- 生物标志物或基因表达模式指导治疗选择的精准医学范式或可应用于ARDS。
核心结论
- ARDS药物治疗选择仍然匮乏,需借助精准医学范式推进特异性药物研发。
研究设计与样本
- 综述:回顾ARDS首次描述后50年间的危险因素、致病机制及血浆和支气管肺泡灌洗液蛋白表达模式研究。
主要发现
- 已识别ARDS的危险因素和致病因素,并表征了患者血浆和支气管肺泡灌洗液的蛋白表达模式。
- 常被提及的缺乏特异性药物原因包括患者异质性、药物反应差异及可能研究了错误靶点。
- 应用生物分子技术与生物信息学在心血管疾病、哮喘等复杂疾病中已取得突破,尤其在精准医学范式下。
临床怎么用
- 可考虑以生物标志物或基因表达模式判断ARDS患者对治疗的反应可能性,推动精准医学 approach。
局限性
- 原文未涉及具体研究样本量、效应值或统计学指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression patterns in plasma and bronchoalveolar lavage fluid from patients with ARDS. Despite this effort, however, pharmacological options for ARDS remain scarce. Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of patients with ARDS, the potential for a differential response to drugs, and the possibility that the wrong targets have been studied. Advances in applied biomolecular technology and bioinformatics have enabled breakthroughs for other complex traits, such as cardiovascular disease or asthma, particularly when a precision medicine paradigm, wherein a biomarker or gene expression pattern indicates a patient's likelihood of responding to a treatment, has been pursued. In this Review, we consider the biological and analytical techniques that could facilitate a precision medicine approach for ARDS.
引用
- Meyer NJ, Calfee CS. Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. Lancet Respir Med. 2017. PMID: 28664850. doi:10.1016/S2213-2600(17)30187-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。